Overall Survival Clinical Trial
Official title:
Clinical Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
To identify the efficiency of Irinotecan, Oxaliplatin, and S1 in patients with previously untreated local regional or metastatic pancreatic cancer.
This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an investigational drug f Irinotecan,Oxaliplatin, and S1, with the goal of determining the OS of advanced pancreatic adenocarcinoma.. Subjects must have a newly diagnosed stage 4 untreated metastatic pancreatic ductal cancer and meet all inclusion/exclusion criteria. Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04025840 -
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
|
Phase 4 | |
| Completed |
NCT04111926 -
Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery
|
Phase 4 | |
| Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03910140 -
TILA-TACE in Treatment of Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT03923400 -
Jejunoileal vs Gastric GIST in the Era of Imatinib.
|
||
| Withdrawn |
NCT02201381 -
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
|
Phase 3 | |
| Recruiting |
NCT05392257 -
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
|
Phase 2 | |
| Recruiting |
NCT05310305 -
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
|
||
| Recruiting |
NCT05310370 -
HRD and Resistance to PAPPi in EOC Patients
|
||
| Recruiting |
NCT05310357 -
Chromosomal Instability in Ovarian Cancer
|
||
| Active, not recruiting |
NCT04245644 -
Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
|
||
| Recruiting |
NCT04245410 -
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
|
||
| Completed |
NCT02980185 -
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT03967457 -
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
|
||
| Recruiting |
NCT04050787 -
Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer
|
N/A | |
| Recruiting |
NCT03892577 -
Real-world Study for Patients With Advanced Hepatobiliary Tumors
|
||
| Not yet recruiting |
NCT02942238 -
Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)
|
N/A | |
| Not yet recruiting |
NCT01236989 -
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC
|
N/A | |
| Recruiting |
NCT05218629 -
Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
|
Phase 2 |